JP6935180B2 - Milk-derived phospholipid-containing powder and its manufacturing method - Google Patents

Description

The present invention relates to a milk-derived phospholipid-containing powder and a method for producing the same.

Soybean lecithin and egg yolk lecithin are widely used as crude phospholipids derived from natural products and as emulsifiers in food production. In recent years, milk-derived phospholipids such as phosphatidylserine, phosphatidylcholine, and sphingomyelin have various physiology. It has been reported to have a function and is drawing attention.
It has been reported that phosphatidylserine and phosphatidylcholine are deeply involved in the development and maintenance of neural and motor functions, and that sphingomyelin has an intestinal maturation function in infants. Sphingomyelin is a substance having a structure in which phosphocholine is bound to a ceramide skeleton consisting of sphingosine and fatty acids, and is present in a large amount in the brain and nerve tissue. In addition, sphingomyelin is abundantly contained in milk, although it is contained only in a small amount in soybean phospholipids and egg yolk phospholipids, and accounts for about 30% of phospholipids in milk.
For this reason, milk-derived phospholipid-rich powders containing high concentrations of milk-derived phospholipids, such as phosphatidylserine, phosphatidylcholine, and sphingomyelin, are widely used as raw materials for functional foods, breast milk substitutes, and pharmaceuticals. can do.

As a powder containing phospholipids derived from milk, a powder produced from butterathrum as a raw material is known (for example, Patent Document 1). In the method described in Patent Document 1, the butteram or the butteram powder reducing solution is adjusted to an acidic pH of 4.0 to 5.0, and the isoelectric point precipitation of the protein produced by adding calcium chloride is removed by centrifugation or the like. Then, after adjusting the pH to neutral, the supernatant is ultrafiltered or microfiltered, and the obtained concentrate is dried to obtain a milk-derived complex lipid-containing powder containing milk-derived phospholipids. ing.

In addition, a method for extracting phospholipids in dairy products using buttermilk powder and other dairy products using a solvent of chloroform / methanol / water (4/8/3) or an organic solvent such as acetone is known. (Patent Document 2). In this method, phospholipids can be concentrated to a high purity of 90% or more.

Japanese Unexamined Patent Publication No. 2007-89535 Japanese Unexamined Patent Publication No. 3-47192

When the protein contained in the starting material is aggregated and precipitated by adjusting the pH as in Patent Document 1 and then centrifuged or the like, the aggregated precipitate having a small particle size cannot be completely removed by centrifugation or the like, and the centrifugal supernatant cannot be removed. Aggregation occurs again while the protein remains acidic. Therefore, protein aggregates remain in the obtained powder. When this powder is used as a food material, the lipids contained in the powder become oil droplets, lactose and minerals are soluble in water, but the remaining protein aggregates become insoluble components. Since the median diameter of these insoluble components is as large as 30 μm or more, a “gritty” texture is felt when eating foods containing food materials.
In addition, when the protein aggregates and precipitates, about 30% of the phospholipids contained in the starting material are incorporated into the precipitate, and the phospholipids are also removed in the step of removing the precipitation of the protein aggregates. The yield recovered as a phospholipid-containing powder is low.
On the other hand, the method using an organic solvent in Patent Document 2 is a method using an organic solvent not approved for the preparation of food materials, and therefore it is difficult to use the obtained milk-derived phospholipid-containing powder in foods. be.
The present invention is intended to solve these problems, and suppresses the residual protein aggregates in a milk-derived phospholipid-containing powder produced from dairy products as a starting material, and yields phospholipids. The challenge is to improve.

The present invention contains 45 to 70% by weight of lipid in the dried product, and the content of milk-derived phospholipid contained in the lipid in the dried product is 20% by weight or more, and is an insoluble component when made into a 5% aqueous solution. Is a milk-derived phospholipid-containing powder having a median diameter of 10 μm or less.
Further, the present invention comprises a step of adding a proteolytic enzyme to an aqueous solution of a starting material containing a dairy product to decompose a protein, a step of inactivating the enzyme after decomposing the protein, and a step of inactivating the enzyme. A method for producing a milk-derived phospholipid-containing powder, which comprises a step of separating the decomposed protein by a membrane treatment to obtain a concentrated solution and a step of drying the concentrated solution.
Further, the present invention comprises a step of acidifying an aqueous solution of a starting material containing a dairy product, a step of removing agglomerates generated by adding calcium chloride by centrifugation or the like to obtain a supernatant, and a step of obtaining a supernatant. A method for producing a milk-derived phospholipid-containing powder, which comprises a step of concentrating by treatment, a step of alkalizing the concentrated solution to solubilize the remaining aggregates, and a step of drying the concentrated solution.

According to the present invention, since the median diameter of the insoluble component when the milk-derived phospholipid-containing powder is made into an aqueous solution is reduced, it is possible to suppress the "gritty" texture even when it is used as a food material.
Further, according to the production method of the present invention, the protein contained in the starting material is reduced in molecular weight by enzymatic decomposition and then removed to suppress the remaining of protein aggregates in the powder, and phospholipids are produced together with the protein. It can be prevented from being removed and the yield of phospholipids can be improved. According to the present invention, the recovery rate of phospholipids in the raw material can be 90% or more, and the yield of the final product can be 15% or more of the solid content of the raw material.
Further, in the conventional production method, the removed protein aggregation precipitate is generated as a semi-solid by-product, so that treatment is required separately. On the other hand, since the membrane permeate generated as a by-product in this production method is a liquid, it is easier to handle than the conventional semi-solid by-product. Further, this liquid contains proteolytic products such as peptides and amino acids obtained by enzymatically decomposing proteins in the raw material, and lactose and minerals, and can be used as a milk solid source for foods and the like.
The milk-derived phospholipid-containing powder of the present invention, or the milk-derived phospholipid-containing powder and by-products obtained by the production method of the present invention can be used as a raw material for functional foods, breast milk substitutes, or pharmaceuticals.

Hereinafter, a method for producing a milk-derived phospholipid-rich powder of the present invention will be described.
The content of phospholipids in buttermilk powder is 5% by weight or more, which is 10 times higher than 0.5% by weight in buttermilk powder. In addition, butter slam is inexpensive because it is produced as a by-product in the production of AMF (Anhydrous Milk Fat, butter oil). Therefore, batase lamb and batase lamb powder can be used as a raw material for milk-derived phospholipid-containing powder.
When butteram powder is used, it is dissolved in water to a concentration of about 10% by weight and reduced, and then a protease, which is a proteolytic enzyme, is added to reduce the molecular weight of the protein in the butteram.
Proteases used for enzyme treatment include animal-derived proteases such as pepsin, chymotrypsin, trypsin, and pancreatin, plant-derived proteases such as papain, bromelain, and ficin, bacteria (lactic acid bacteria, bacilli, actinomycetes), and fungi (mushrooms, yeast, and Any protease such as endoprotease or exoprotease produced by microorganisms such as mold) or algae can be used. In particular, the protein resolution of neutral / alkaline proteases produced by the genera Bacillus and Aspergillus is high and preferable. Further, the enzyme may be in any form regardless of whether it is a liquid or powder such as a purified enzyme, a semi-purified enzyme, a crude enzyme, and a crushed bacterial cell. The solvent used for preparing the enzyme solution is not particularly limited as long as the enzyme does not denature or inactivate and there is no problem in food hygiene.
Specific examples of usable proteases include, for example, Sumiteam FP-G (manufactured by Shin Nihon Kagaku Kogyo Co., Ltd.), Sumiteam LP-50D (manufactured by Shin Nihon Kagaku Kogyo Co., Ltd.), Sumiteam MP (manufactured by Shin Nihon Kagaku Kogyo Co., Ltd.), Protin SD. -AY10 (Amano Enzyme), Protin NY100 (Amano Enzyme), Peptidase R (Amano Enzyme), Proteax (Amano Enzyme), Protea M "Amano" SD (Amano Enzyme), Protearator P "Amano" 6SD (manufactured by Amano Enzyme), Bromeline F (manufactured by Amano Enzyme), Samoase PC10F (manufactured by Amano Enzyme), Punchdase NP-2 (manufactured by Yakult Pharmaceutical Co., Ltd.), Aroase NP-10 (manufactured by Yakult Pharmaceutical Chemicals) Orientase 22BF (manufactured by HBI), Orientase OP (manufactured by HBI), Nukureishin (manufactured by HBI), Multifect PR 6L (manufactured by DuPont), Multifect PR 7L (manufactured by DuPont), Actinase AS (manufactured by Kaken Pharma), Denateam AP (manufactured by Nagase ChemteX), Maxipro PSP (manufactured by DSM), Maxipro FPC (manufactured by DSM), Enzyme NBS-100 (manufactured by Rakuto Kasei), Alcalase (manufactured by Novozymes) (Made), Protamex (manufactured by Novozymes), Flavorzyme (manufactured by Novozymes).
Regarding the conditions of the enzyme treatment, the enzyme reaction temperature and pH do not necessarily have to be the optimum temperature and pH of the enzyme, and it may be preferable to react at a temperature and pH that can prevent flavor deterioration and spoilage. The reaction time is 5 minutes to 24 hours, but is preferably within 5 hours from the viewpoint of microbial growth.
The enzyme to be added may be one type, but it is also possible to use two or more types in combination.

The obtained enzymatically decomposed bataselam contains lipid components including proteins, peptides, amino acids, lactose, minerals, and phospholipids of interest. Membrane separation techniques are applied to remove and reduce components other than phospholipids. Proteins and lipids contained in butteram cannot permeate ultrafiltration membranes or microfiltration membranes. On the other hand, peptides, amino acids and other components such as lactose and minerals produced by reducing the molecular weight of proteins can permeate through ultrafiltration membranes or microfiltration membranes. Therefore, by concentrating and dialyzing the protease-treated bataselam with an ultrafiltration membrane or a microfiltration membrane, components other than lipids can be removed on the permeate side and phospholipids can be concentrated. The ratio of lipid component to the solid content of the obtained concentrate is as high as 45 to 70% by weight, but it can be easily powdered by a spray dryer commonly used in the food industry, and the phospholipid content is 20% by weight. A powder of% or more can be obtained.
The membrane type used for the membrane treatment may be an organic membrane or an inorganic membrane, such as polyvinylidene fluoride, polysulfone, polyethersulfone, polytetrafluoroethylene, polyethylene, polypropylene, polyimide, polyetherimide, polycarbonate, high molecular weight polyvinyl alcohol, etc. It may be made of the polymer of the above, or may be made of an inorganic substance such as ceramics, zeolite, zirconia, silica, or alumina. Further, as the shape of the separation membrane, any shape such as a flat membrane, a hollow fiber membrane, a spiral membrane, and a ceramics membrane can be used.
The separation membrane can be either an ultrafiltration membrane or a microfiltration membrane, or both, but the peptides, amino acids, lactose, and minerals in the enzymatically decomposed bataselam are removed as much as possible, and the lipid fraction is placed on the concentrate side as much as possible. It is preferable to use a microfiltration membrane, more preferably a microfiltration membrane having a fractionated particle size of 0.1 to 1.4 μm, in order to retain it.
As the drying means, for example, freeze-drying, vacuum drying, hot air drying and the like can be appropriately used.
The obtained powder of the present invention has a low protein, sugar content and mineral content, contains 45 to 70% by weight of lipid in the dried product, and contains 20% by weight or more of phospholipid among the lipids in the dried product. It is a milk-derived phospholipid-containing powder in which the median diameter of the insoluble component when made into a 5% aqueous solution is 10 μm or less.
The supernatant obtained by adjusting the batteram or batteram powder reducing solution to an acidity of pH 4.0 to 5.0 and removing the isoelectric point precipitation of the protein produced by adding calcium chloride by centrifugation or the like. The protein aggregates are solubilized and dried by ultrafiltration or microfiltration to concentrate the membrane, and adjusting the pH of the obtained concentrate to an alkalinity of pH 9.0 to 10.0. It is possible to obtain a milk-derived phospholipid-containing powder similar to the above, but it is inferior to the above-mentioned method in terms of the recovery rate of phospholipids and the yield of the obtained powder.

Next, the present invention will be specifically described with reference to Examples.

Batastram reduction liquid with a solid content of 10% by weight by adding 180 kg of water heated to 50 ° C to 20 kg of raw material batase lamb powder (TATUA) (of which 3.0 kg of lipid and 1.6 kg of phospholipid) and stirring and dissolving. Was prepared. Aspergillus oryzae-derived protease (Sumiteam LP-50D, Shin Nihon Kagaku Kogyo Co., Ltd.) was added to this bataseram reducing solution in an amount of 1% by weight based on the protein weight of the bataserum powder, and reacted at 50 ° C. for 5 hours to enzymatically decompose the bataseram solution. Got The obtained enzymatically decomposed bataselam solution was subjected to microfiltration membrane treatment with a fractionated particle size of 1.4 μm after inactivating the enzyme, and the concentrated solution was recovered and dried by freeze-drying treatment in Examples. Milk-derived phospholipid powder was obtained.
The weight of the obtained powder was 5.0 kg, of which 2.9 kg of lipid and 1.5 kg of phospholipid, 58% by weight of the lipid in the dried product of the obtained powder, and 30% of the phospholipid derived from milk in the dried product. It was% by weight. In addition, the recovery rate of phospholipids in the powder obtained from the raw material batase lamb powder was 94%, the yield was 25%, and the median diameter of the insoluble component (cumulative on a volume basis) when the obtained powder was made into a 5% aqueous solution. 50% particle size) was measured by a laser diffraction type particle size distribution meter and found to be 5.1 μm.
The lipid and phospholipid contents of the milk-derived phospholipid powder of the present invention were quantified by the following method.
After dissolving 1 g of milk-derived phospholipid powder in 5 mL of a 1.25 wt% potassium oxalate aqueous solution, add 6 mL of ethanol, 15 mL of diethyl ether, and 15 mL of petroleum ether in that order and shake horizontally to extract the lipid into a solvent phase to obtain a solvent phase. After recovery, the solvent was volatilized and the lipid content was calculated from the weight of the remaining oil. Add 0.5 mL of perchloric acid and 2.0 mL of nitric acid to the above oil content of 25 mg, heat at 100 ° C for 60 minutes, add 3 mL of nitric acid, and add 3 mL of nitric acid to 120 ° C to 140 ° C in 10 ° C increments for 10 minutes at 150 ° C to 170 ° C. Until then, the mixture was heated at 10 ° C. for 30 minutes for wet ashing, and then inorganic phosphorus was quantified using Phospha C-Test Wako. The obtained amount of inorganic phosphorus was multiplied by a phosphatidylserine conversion coefficient of 25.4 to convert it into a phospholipid amount.

[Comparative Example 1]
Batastram reduction liquid with a solid content of 10% by weight by adding 180 kg of water heated to 50 ° C to 20 kg of the raw material batase lamb powder (TATUA) (of which 3.0 kg of lipid and 1.6 kg of phospholipid) and stirring and dissolving. Was prepared. The pH was adjusted to 4.4 by adding 10% hydrochloric acid to this bataselam reduced solution. At the same time, calcium chloride was added so as to be 0.02% by weight of the total amount, and then the casein was aggregated by holding at 50 ° C. for 30 minutes. The produced casein precipitate was completely removed by treatment with a centrifuge to obtain a supernatant. This supernatant was collected and lyophilized to obtain a powder.
The weight of the obtained powder was 2.4 kg, of which 1.4 kg of lipid and 0.7 kg of phospholipid, 58% by weight of the lipid in the dried product of the obtained powder, and 29% of the phospholipid derived from milk in the dried product. It was% by weight. In addition, the recovery rate of phospholipids in the powder obtained from the raw material batase lamb powder was 44%, and the yield was 12%, which were poorer in recovery rate and yield of phospholipids as compared with Example 1.
When the median diameter (cumulative 50% particle diameter based on volume) of the insoluble component when the obtained powder was made into a 5% aqueous solution was measured by a laser diffraction type particle size distribution meter, it was 32.6 μm, which was larger than that of Example 1. ..
[Comparative Example 2]
Batastram reduction liquid with a solid content of 10% by weight by adding 180 kg of water heated to 50 ° C to 20 kg of raw material batase lamb powder (TATUA) (of which 3.0 kg of lipid and 1.6 kg of phospholipid) and stirring and dissolving. Was prepared. The obtained bataselam powder reduced solution was subjected to microfiltration membrane treatment with a fractionated particle size of 1.4 μm, the concentrated solution was recovered, and dried by freeze-drying treatment to obtain a milk-derived phospholipid powder.
Of the 8.5 kg of the obtained powder, 2.9 kg of lipid, 1.5 kg of phospholipid, and 3.9 kg of protein, 34% by weight of the lipid in the dried product of the obtained powder, and the phospholipid derived from milk was the dried product. Medium 18% by weight, which was lower than that of Example 1. It is considered that this is because the protein in the raw material was not sufficiently removed on the permeate side, and the lipid and phospholipid contents were relatively low. The recovery rate of phospholipids in the powder obtained from the raw material batase lamb powder was 94%, and the yield was 43%.
The median diameter (cumulative 50% particle diameter on a volume basis) of the insoluble component when the obtained powder was made into a 5% aqueous solution was measured by a laser diffraction type particle size distribution meter and found to be 0.44 μm.
[Comparative Example 3]
Batastram reduced liquid with a solid content of 10% by weight by adding 180 kg of water heated to 50 ° C to 20 kg of raw material bataseram powder (TATUA) (of which 3.0 kg of lipid and 1.6 g of phospholipid) and stirring and dissolving. Was prepared. Aspergillus oryzae-derived protease (Sumiteam LP-50D, Shin Nihon Kagaku Kogyo Co., Ltd.) was added to this bataseram reducing solution in an amount of 1% by weight based on the protein weight of the bataserum powder, and reacted at 50 ° C. for 1 hour to enzymatically decompose the bataseram solution. Got The obtained enzymatically decomposed bataselam solution was subjected to microfiltration membrane treatment with a fractionated particle size of 1.4 μm after inactivating the enzyme, and the concentrated solution was recovered and dried by freeze-drying treatment in Examples. Milk-derived phospholipid powder was obtained.
Of the 7.8 kg of the obtained powder, lipid was 2.9 kg, phospholipid was 1.5 kg, and protein was 3.2 kg. The lipid in the dried product of the obtained powder was 37% by weight, and the phospholipid derived from milk was the dried product. Medium 19% by weight, which was lower than that of Example 1. It is considered that this is because the protein in the raw material was not sufficiently decomposed, so that the removal to the permeate side was insufficient, and the lipid and phospholipid contents were relatively low. The recovery rate of phospholipids in the powder obtained from the raw material batase lamb powder was 94%, and the yield was 39%.
The median diameter (cumulative 50% particle diameter on a volume basis) of the insoluble component when the obtained powder was made into a 5% aqueous solution was measured by a laser diffraction type particle size distribution meter and found to be 0.42 μm.

Batastram powder with a solid content of 10% by weight by adding 450 kg of water heated to 50 ° C to 50 kg of the raw material batase lamb (Uelzena) (5 kg of solids, 0.65 kg of lipids and 0.33 kg of phospholipids) and stirring and dissolving. A reducing solution was prepared. Aspergillus oryzae-derived protease (Sumiteam FP-G, Shin Nihon Kagaku Kogyo Co., Ltd.) was added to this batase lamb powder reduction solution in an amount of 1% by weight based on the protein weight of the batase lamb powder, and reacted at 50 ° C. for 5 hours to enzymatically decompose the batase lamb. I got the liquid. The obtained enzymatically decomposed bataselam solution was subjected to ultrafiltration membrane treatment with a fractional molecular weight of 10 kDa after inactivating the enzyme, the concentrated solution was recovered, and dried by freeze-drying treatment in this example. Milk-derived phospholipid powder was obtained.
The weight of the obtained powder was 1.1 kg, of which the lipid was 0.61 kg and the phospholipid was 0.31. kg, the lipid in the dried product of the obtained powder was 55% by weight, and the phospholipid derived from milk was in the dried product. It contained 28% by weight, and the recovery rate of phospholipids from the raw material bataseram powder was 91%, and the yield was 22.0%.
The median diameter (cumulative 50% particle diameter on a volume basis) of the insoluble component when the obtained powder was made into a 5% aqueous solution was measured by a laser diffraction type particle size distribution meter and found to be 7.3 μm.

[Test Example 1]
In order to confirm the effect of the difference in median diameter of the obtained milk-derived phospholipid powder on the “grainy” texture during eating, Example 1, Example 2, Comparative Example 1, Comparative Example 2 and Comparative Example 3 A 5% aqueous solution of the powder obtained in (1) was prepared and a sensory evaluation was carried out. Table 1 shows the sensory evaluation results. In addition, the lipid content in the dried product of the obtained powder and the phospholipid content derived from milk are shown.
The 5% aqueous solution of the milk-derived phospholipid powder obtained in Examples 1 and 2 had a median diameter of 10 μm or less as an insoluble component, so that no roughness was felt. On the other hand, in the 5% aqueous solution of the milk-derived phospholipid powder obtained in Comparative Example 1, an insoluble component having a median diameter of 30 μm or more remained, so that a roughness was felt. In addition, the 5% aqueous solution of the milk-derived phospholipid powder obtained in Comparative Examples 2 and 3 did not feel grainy.

Batastram powder with a solid content of 10% by weight by adding 450 kg of water heated to 50 ° C to 50 kg of the raw material batase lamb (Uelzena) (5 kg of solids, 0.65 kg of lipids and 0.33 kg of phospholipids) and stirring and dissolving. A reducing solution was prepared. To this reduced batase lamb powder, 1% by weight of protein weight of 4 kinds of proteases having different origins was added and reacted at 50 ° C. for 5 hours to obtain an enzymatically decomposed batase lamb solution. The obtained enzymatically decomposed bataselam solution was subjected to microfiltration membrane treatment with a fractionated particle size of 1.4 μm after inactivating the enzyme, the concentrated solution was recovered, and dried by freeze-drying treatment in this example. Milk-derived phospholipid powder was obtained.
In Table 2, the median diameter (cumulative 50% particle diameter on a volume basis) of the insoluble component when each of the protease used for the enzyme treatment and the obtained powder was made into a 5% aqueous solution was measured by a laser diffraction type particle size distribution meter. The result is shown. The milk-derived phospholipid powder prepared in this example had a median diameter of 10 μm or less as an insoluble component when made into a 5% aqueous solution, regardless of the protease species used for the enzyme treatment. When the sensory evaluation was carried out by preparing a 5% aqueous solution of these powders, no roughness was felt as in the results of Examples 1 and 2.

Batastram reduction liquid with a solid content of 10% by weight by adding 180 kg of water heated to 50 ° C to 20 kg of the raw material batase lamb powder (TATUA) (of which 3.0 kg of lipid and 1.6 kg of phospholipid) and stirring and dissolving. Was prepared. The pH was adjusted to 4.4 by adding 10% hydrochloric acid to this bataselam reduced solution. At the same time, calcium chloride was added so as to be 0.02% by weight of the total amount, and then the casein was aggregated by holding at 50 ° C. for 30 minutes. The produced casein precipitate was completely removed by treatment with a centrifuge to obtain a supernatant. This supernatant was treated with a microfiltration membrane having a fractionated particle size of 1.4 μm, and the concentrated solution was recovered. Sodium hydroxide was added so that the pH of this concentrated solution was 9.5 to solubilize the remaining protein aggregates, and a powder was obtained by freeze-drying treatment.
The weight of the obtained powder was 2.5 kg, of which 1.4 kg of lipid and 0.7 kg of phospholipid, 56% by weight of the lipid in the dried product of the obtained powder, and 28% of the phospholipid derived from milk in the dried product. It was% by weight. The recovery rate of phospholipids in the powder obtained from the raw material batase lamb powder was 44%, and the yield was 12%. The median diameter (cumulative 50% particle diameter on a volume basis) of the insoluble component when the obtained powder was made into a 5% aqueous solution was measured by a laser diffraction type particle size distribution meter and found to be 9.6 μm.
The median diameter was about the same as in Example 1, but the recovery rate and yield of phospholipids were poor as compared with Example 1.

Claims (9)

A step of adjusting the starting material including dairy products to have a pH of 4.0 to 5.0, adding calcium chloride to remove the precipitate formed, and obtaining a supernatant.
The process of concentrating the supernatant by membrane treatment and
The process of adjusting the pH of the concentrate to 9.0-10.0 to solubilize and dry the protein aggregates, and
A method for producing a milk-derived phospholipid-containing powder, which comprises. The production method according to claim 1, wherein the dairy product is at least one of buttermilk, buttermilk powder reducing liquid, buttermilk, and buttermilk powder reducing liquid. A step of adding a proteolytic enzyme to a starting material containing at least one dairy product of buttermilk, buttermilk powder reduced solution, buttermilk, and buttermilk powder reduced solution to decompose proteins.
After decomposing the protein, the step of inactivating the proteolytic enzyme and
A step of inactivating the proteolytic enzyme and then separating the degraded protein by membrane treatment to obtain a concentrated solution.
A method for producing a milk-derived phospholipid-containing powder, which comprises a step of drying the concentrated liquid. The membrane treatment method according to claim 3, characterized in that the treatment by microfiltration follows fractionated particle size 1.4μ m. The production method according to claim 3, wherein the membrane treatment is a treatment by ultrafiltration having a molecular weight cut-off of 10 kDa or more. The invention according to any one of claims 3 to 5, wherein the proteolytic enzyme is at least one enzyme selected from an animal-derived protease, a plant-derived protease, a bacterial-derived protease, a fungal-derived protease, and an algae-derived protease. Manufacturing method.
The production method according to any one of claims 3 to 6, wherein the proteolytic enzyme is derived from the genus Bacillus. The proteolytic enzyme, The process according to any one of claims 3-6, characterized in that the derived from the genus Aspergillus. The production method according to any one of claims 3 to 8, wherein the proteolytic enzyme is a neutral or alkaline enzyme.